DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Targeting multiple dyslipidemias with fixed combinations--focus on extended release niacin and simvastatin.

Author(s): Pandian A, Arora A, Sperling LS, Khan BV

Affiliation(s): Emory University School of Medicine and Grady Memorial Hospital Vascular Research, Atlanta, Georgia 30303, USA.

Publication date & source: 2008, Vasc Health Risk Manag., 4(5):1001-9.

Publication type: Review

Dyslipidemia is a major risk factor in the initiation and progression of cardiovascular diseases such as atherosclerosis. Several pharmacological agents have been developed over the past 50 years which target various lipid components such as low density lipoprotein (LDL) cholesterol, triglyceride, and high density lipoprotein (HDL) cholesterol. Similar to other risk factors such as hypertension and diabetes mellitus, the management of dyslipidemia can be complicated and may require combination therapy for effective treatment. This review discusses the biochemical mechanisms of action and clinical uses for simvastatin (the most widely available and commercially prescribed statin) and niacin, and the combination of these agents in the management and treatment of dyslipidemia.

Page last updated: 2009-10-20

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017